Navigation Links
Optimizing the Use of Health Outcomes Data in the Marketplace
Date:9/21/2011

CHAPEL HILL, N.C., Sept. 21, 2011 /PRNewswire/ -- Pharmaceutical and biotechnology organizations use health outcomes data to support a variety of product-related initiatives, from treatment guidelines to formulary decisions. With health outcomes data playing such a pivotal role in a product's performance, it's important for organizations to optimize the use of Health Outcomes data.

To help organizations understand current approaches to effectively using health outcomes data in the marketplace, Best Practices, LLC has published a study that examines the internal and external uses of Health Outcomes data for promotional and strategic purposes.

The study, Best Practices in Utilizing Health Outcomes Data, provides comparative data from 2009 and 2011 that illustrate shifting attitudes for how organizations utilize health outcomes data.

Organizations in 2011 used health outcomes data internally mostly for determining market access and scientific publication strategies. Relative to 2009, the importance of using health outcomes data internally for reimbursement decisions increased 24 percent, from 45 percent in 2009 to 69 percent in 2011, according to the study. Meanwhile, in 2011 and 2009, reimbursement and drug formulary decisions were the main use of health outcomes data for interactions with managed care, according to the study.

The 51-page study reflects current approaches to health outcomes data utilization at 16 biopharma organizations; the 2009 data is based on a benchmark class of 29 companies.

The insights in this new study will help pharmaceutical and biotech organizations compare their use of health outcomes data in promotional and internal settings with that of leading organizations. The study also examines the pressing regulatory issues raised by the different uses of health outcomes data.

Key topics covered in this research include:

  • Structure and Reporting Lines of Authority
  • Use of Health Outcomes Data Proactively and Retrospectively
  • How Health Outcomes Data is Utilized within Different Groups
  • Health Outcomes Review Process and Structure
  • Best Practices in Health Outcomes Utilization

To download a complimentary study excerpt, go to: http://www3.best-in-class.com/rr1119.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a research and consulting firm that has served many of the world's 50 top pharmaceutical companies.  For more than 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.  For more information about the company, go to www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus and the Medco Research Institute® to Evaluate the Use of Prometheus Thiopurine Metabolite Testing for Optimizing Treatment of Inflammatory Bowel Disease Patients
2. Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
3. Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas
4. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
5. Health Strategies Group Introduces New One-Stop Suite of Intelligence Services for Optimizing Marketing and Sales Resources in the Institutional Channel
6. Innovative Partnership Helps Improve Medical Research by Optimizing Clinical Trials
7. RadMD Offers Tips on Optimizing Clinical Trial Efficiency
8. At Home Healthcare Expands Telehealth Program With Cardiocom® Telehealth Technology
9. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
10. Genomic Health to Present at the JMP Securities Healthcare Conference
11. Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):